Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL586081 | 0.99 | KDM4E (0.31) | KDM4EALDH1A1THRATHRB | |
| SCHEMBL2330197 | 0.89 | — | — | |
| Hydrochloric Acid SCHEMBL584870 | 0.88 | SLC2A1 (0.30) | — | |
| Hydrochloric Acid SCHEMBL585791 | 0.87 | — | — | |
| SCHEMBL21523874 | 0.81 | RARB (0.40) | KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL27856205 | 0.79 | RARB (0.38) | KDM4EALDH1A1 | |
| SCHEMBL5432873 | 0.77 | AGER (0.38) | — | |
| SCHEMBL585095 | 0.76 | RARB (0.36) | KDM4EALDH1A1 | |
| SCHEMBL2328568 | 0.74 | LSS (0.37) | KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL585264 | 0.73 | LSS (0.36) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9326511-B2 | Methods of inhibiting microbial biofilms | DESTINY PHARMA LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| EP-2355816-B1 | PORPHYRIN COMPOUNDS FOR KILLING, INHIBITING OR PREVENTING THE GROWTH OF MICROBIAL BIOFILMS | DESTINY PHARMA LTD (GB) | 2014-05-14 | — | — | EP | disclosed |
| US-20110262511-A1 | Novel Uses | DESTINY PHARMA LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
| EP-2355816-A2 | NOVEL USES | Destiny Pharma Limited (GB) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010046663-A2 | NOVEL USES | DESTINY PHARMA LIMITED (GB) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262511-A1 | Novel Uses | XDH, F12, ZFX | KDM4E 1716/4885ALDH1A1 1391/4885THRA 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.